摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]oxazolo[5,4-b]pyridine

中文名称
——
中文别名
——
英文名称
4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]oxazolo[5,4-b]pyridine
英文别名
8-methyl-5-methylamino-2-phenyl-8H-imidazo[4,5-d]oxazolo[5,4-b]pyridine;N,12-dimethyl-4-phenyl-5-oxa-3,7,10,12-tetraazatricyclo[7.3.0.0^{2,6}]dodeca-1(9),2(6),3,7,10-pentaen-8-amine;N,12-dimethyl-4-phenyl-5-oxa-3,7,10,12-tetrazatricyclo[7.3.0.02,6]dodeca-1(9),2(6),3,7,10-pentaen-8-amine
4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]oxazolo[5,4-b]pyridine化学式
CAS
——
化学式
C15H13N5O
mdl
——
分子量
279.301
InChiKey
SOFBJAGASYHSSD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    68.8
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]oxazolo[5,4-b]pyridine盐酸 作用下, 以 为溶剂, 生成 8-methyl-5-methylamino-2-phenyl-8H-imidazo[4,5-d]oxazolo[5,4-b]pyridine hydrochloride
    参考文献:
    名称:
    [EN] OXAZOLYL - AND THIAZOLYL - PURINE BASED TRICYCLIC COMPOUNDS.
    [FR] COMPOSES TRICYCLIQUES A BASE D'OXAZOLO[4,5-B]PYRIDINE CONDENSEE A UN IMIDAZO ET DE THIAZOLO[4,5-B]PYRIDINE CONDENSEE A UN IMIDAZO, ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI
    摘要:
    公开号:
    WO2004106293A3
  • 作为产物:
    描述:
    7-chloro-4-methyl-2-phenyl-4H-imidazo[4,5-d]oxazolo[5,4-b]-pyridine盐酸甲胺N,N-二异丙基乙胺 作用下, 以 正丁醇 为溶剂, 反应 4.0h, 以19%的产率得到4-methyl-7-methylamino-2-phenyl-4H-imidazo[4,5-d]oxazolo[5,4-b]pyridine
    参考文献:
    名称:
    Novel Tricyclic Inhibitors of IκB Kinase
    摘要:
    The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.
    DOI:
    10.1021/jm8015816
点击查看最新优质反应信息

文献信息

  • Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
    申请人:Pitts J. William
    公开号:US20060217412A1
    公开(公告)日:2006-09-28
    The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    本发明提供了具有式(I)的嘧唑并咪唑基三环化合物,其中R1、R2、R3、R4、R5和R6如本文所述。本发明还提供了包含这些化合物的制药组合物,以及使用这些化合物治疗炎症和免疫性疾病的方法。
  • Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
    申请人:Pitts J. William
    公开号:US20050101626A1
    公开(公告)日:2005-05-12
    The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
    本发明提供了具有式(I)的吡唑嘌呤基三环化合物、 其中 R 1 , R 2 , R 3 , R 4 , R 5 和 R 6 如本文所述。本发明进一步提供了包含此类化合物的药物组合物,以及使用此类化合物治疗炎症和免疫疾病的方法。
  • US7176214B2
    申请人:——
    公开号:US7176214B2
    公开(公告)日:2007-02-13
  • [EN] OXAZOLYL - AND THIAZOLYL - PURINE BASED TRICYCLIC COMPOUNDS.<br/>[FR] COMPOSES TRICYCLIQUES A BASE D'OXAZOLO[4,5-B]PYRIDINE CONDENSEE A UN IMIDAZO ET DE THIAZOLO[4,5-B]PYRIDINE CONDENSEE A UN IMIDAZO, ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2004106293A3
    公开(公告)日:2005-03-24
  • Novel Tricyclic Inhibitors of IκB Kinase
    作者:James Kempson、Steven H. Spergel、Junqing Guo、Claude Quesnelle、Patrice Gill、Dominique Belanger、Alaric J. Dyckman、Tianle Li、Scott H. Watterson、Charles M. Langevine、Jagabandhu Das、Robert V. Moquin、Joseph A. Furch、Anne Marinier、Marco Dodier、Alain Martel、David Nirschl、Katy Van Kirk、James R. Burke、Mark A. Pattoli、Kathleen Gillooly、Kim W. McIntyre、Laishun Chen、Zheng Yang、Punit H. Marathe、David Wang-Iverson、John H. Dodd、Murray McKinnon、Joel C. Barrish、William J. Pitts
    DOI:10.1021/jm8015816
    日期:2009.4.9
    The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺